Now, domestic companies in patent war
April 03, 2013  09:10
In a twist in patent wars, a domestic generic company has dragged another to court. 

To protect its monopoly, domestic generic major Sun Pharma joined hands with MSD India, Merck's subsidiary , dragging domestic company Glenmark to the Delhi high court, seeking an injunction over the marketing of blockbuster diabetes drug, Januvia (sitagliptin).

Recently, Glenmark launched a more affordable version of Merck's blockbuster Januvia in the domestic market heightening tensions between MNCs and domestic generic companies, already embroiled in several patent disputes. 

Till now, turf wars between Big Pharma and generic companies , were largely restricted to exorbitantly-priced life saving drugs for cancer and HIV, have now spilled over to other chronic ailments like diabetes, and threaten to change the dynamics of the over Rs 70,000 crore Indian pharma market.

« Back to LIVE

TOP STORIES